Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437674 | 0.90 | DRD2 (0.50) | ABCG2DRD2KMT2A | |
| SCHEMBL12437529 | 0.87 | MCHR1 (0.60) | ABCG2DRD2KMT2A | |
| SCHEMBL12437531 | 0.86 | KMT2A (0.56) | ABCG2DRD2KMT2A | |
| SCHEMBL12437407 | 0.86 | DRD2 (0.54) | DRD2KMT2A | |
| SCHEMBL12437679 | 0.85 | SLC5A7 (0.53) | KMT2A | |
| SCHEMBL12437746 | 0.79 | OPRK1 (0.45) | KMT2A | |
| SCHEMBL12437372 | 0.78 | MCHR1 (0.51) | ABCG2DRD2KMT2A | |
| SCHEMBL12437087 | 0.75 | MEN1 (0.47) | KMT2A | |
| SCHEMBL12437762 | 0.74 | HRH3 (0.52) | KMT2A | |
| SCHEMBL16233191 | 0.73 | ABCG2 (0.74) | ABCG2DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | ABCG2 2447/4885DRD2 1842/4885KMT2A 2446/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | ABCG2 2447/4885DRD2 1842/4885KMT2A 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.